Chris Hill (@dochill1982.bsky.social)

Anti-Rituximab Antibodies in Primary Membranous Nephropathy: Time for Routine Monitoring in Clinical Practice? Rituximab, a chimeric monoclonal antibody that targets the CD20 molecule on the surface of B cells, has been part of the therapeutic armamentarium for glomerular diseases since the early 2000s. Over the past decade, it has emerged as a standard-of-care treatment for primary membranous nephropathy (MN) (pMN) and is being increasingly used in steroid-dependent nephrotic syndrome for both pediatric and adult patients.1 The relapsing nature of these renal diseases may require repeated cycles of rituximab to achieve and maintain remission. https://www.kireports.org/article/S2468-0249(25)00405-X/fulltext